This research focuses on investigating the utility of using CSA measures in two distinct patient groups, including a group of consented clinic patients with different NCDs (Group A) and a highly characterized group of research participants that includes healthy controls, Alzheimer’s disease patients, and mild cognitive impairment patients (Group B), and to follow these two groups in prospective, longitudinal studies to correlate spontaneous speech measures with standardized linguistic, neuropsychological, and biological measures.

Primary progressive aphasia in Turkish: Quantiative assessment of agrammatism in agglutinative language
European Commission Marie Curie Actions 7th Framework Programme
PI: Mustafa Seçkin

